NR vs NMN is the most-asked NAD+-precursor question. The honest answer is that both compounds raise plasma NAD+ reliably, both lack hard outcome trials, and the choice is closer than the marketing on either side suggests. This guide covers the evidence on each, the mechanistic differences, and what actually matters for the decision.
What both compounds do
Both NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are vitamin B3 precursors that the body converts to NAD+ (nicotinamide adenine dinucleotide), the central electron-carrier coenzyme in cellular metabolism. NAD+ levels decline with age in most tissues, and the longevity hypothesis is that raising NAD+ via supplemental precursors slows the cellular phenotype of aging.
Both compounds reliably raise plasma NAD+ 30-90% at oral doses of 250-1,000 mg/day across multiple human trials. Tissue NAD+ rises are inconsistent for both (skeletal muscle is the only routinely-biopsiable tissue; liver, brain, and heart NAD+ effects in humans are inferred from animal models). Hard clinical outcomes (mortality, frailty progression, cardiovascular events) have not been measured in completed trials for either compound.
The compounds are biochemically related. NR is one biosynthetic step upstream of NMN in the salvage pathway: NR is phosphorylated by nicotinamide riboside kinase (NRK) to NMN, which is then adenylylated by NMNAT to NAD+. So NR has to pass through NMN-territory anyway. The mechanistic case for one being substantially superior to the other depends on debated tissue-uptake details (the Slc12a8 NMN transporter, NRK expression patterns) that don't decisively favor either.
Trial evidence comparison
NR human trials (more numerous, larger safety database):
- Trammell 2016 (n=12, single-dose PK): established oral bioavailability and clean acute safety Trammell SA et al 2016
- Martens 2018 (n=24, 500 mg/day for 6 weeks in healthy older adults): reduced systolic BP ~6 mmHg, reduced arterial stiffness Martens CR et al 2018
- Dollerup 2018 (n=40, 1,000 mg/day for 12 weeks in obese non-diabetic men): no insulin sensitivity change despite plasma NAD+ rise
- Multiple subsequent trials in Parkinson's, aging, and athletic populations
NMN human trials (growing, smaller safety database):
- Yoshino 2021 (n=25, 250 mg/day for 10 weeks in prediabetic women): improved muscle insulin sensitivity Yoshino M et al 2021
- Igarashi 2022 (n=42, 250 mg/day for 12 weeks in older Japanese men): improved gait speed, grip strength
- Yamaguchi 2022 (single-dose PK): dose-dependent plasma NAD+ rise
- 2024 meta-analysis (4 RCTs, 196 participants): small but significant improvements in walking distance and fatigue
The pattern: NR has the larger safety database and the cardiovascular surrogate signal; NMN has the more impressive muscle/insulin sensitivity surrogate signal in selected populations. Neither has hard outcome data.
For users prioritizing safety depth, NR has the edge. For users hunting the strongest surrogate biomarker effect, NMN has slightly more impressive recent data. The advantage for either is modest.
Practical differences
Cost: NR (Niagen) and NMN are both expensive supplements. NR runs roughly 30-60 dollars per month at 500 mg/day; NMN runs 30-80 dollars per month at 500 mg/day. Generic versions of both are cheaper but quality variable.
Availability: NMN has had US regulatory headwinds (the 2022 FDA dietary-supplement determination). It remains widely sold in the US in 2026 but some major retailers have de-listed it. NR is uncomplicated regulatorily.
Bioavailability data: NR has more rigorous PK trials; NMN's PK is less thoroughly characterized in humans (though improved by 2023-2024).
Pterostilbene combination: NR + pterostilbene is the Basis (Elysium Health) formulation, with mechanistic appeal (sirtuin activation). NMN is sometimes combined with TMG (trimethylglycine) for methylation support. Neither combination has decisive comparative evidence.
Sublingual / liposomal forms: marketed for both but lack comparative-superiority evidence vs standard oral capsule.
Who should choose what
Choose NR if:
- You prioritize the larger safety database (longest-running human trials)
- You want the cardiovascular surrogate evidence (Martens 2018)
- You're combining with pterostilbene for the Basis-style protocol
- You want regulatory simplicity (no NMN-style FDA wrinkles)
Choose NMN if:
- You're targeting muscle / insulin sensitivity outcomes (Yoshino 2021 strongest signal)
- You have or are at risk for prediabetic metabolic profile
- You're following Sinclair-style longevity protocol cosmologically
- Cost-availability is favorable in your market
Choose neither if:
- You don't have the boring foundation in place (creatine, omega-3, vitamin D3+K2, magnesium glycinate, exercise, sleep)
- You're under 40 with no specific metabolic risk factors
- The 30-80 dollar/month cost would be better spent elsewhere
NAD+ precursors sit at Tier-C in the biohacking supplements framework: mechanistically interesting, weak human evidence at hard outcomes, and the Tier-A foundation should come first.
Stacking and timing
Both compounds:
- Take in the morning, with or without food (with food slightly slows but doesn't reduce absorption)
- 250-500 mg/day for typical use; 1,000 mg/day for users following published trial protocols
- No cycling required; cumulative tolerance has not been observed
- Pair with TMG (trimethylglycine) at 500-1,500 mg/day if running high doses for methylation support (theoretical case; trial evidence absent)
Don't pair NR + NMN. Mechanistically redundant; stacking them costs more without better effect than either alone.
Don't expect dramatic subjective effects. Plasma NAD+ rises within days; surrogate biomarker effects (BP, insulin sensitivity, muscle function) take 6-12 weeks. Most users report no perceptible day-to-day change even when biomarkers shift.
What the marketing oversells
- Anti-aging-rhetoric claims: not supported by hard outcome data. Plasma NAD+ rises; aging biomarkers don't reliably reverse in humans on supplemental NAD+ precursors.
- "David Sinclair takes it" as evidence: a researcher's personal supplement choice is not clinical-grade evidence.
- Claimed "superior bioavailability" of one form vs other: the comparative trial evidence is thin on either side.
- Sublingual / liposomal premium pricing: lacks comparative human evidence supporting the premium.
- Combination products with 8-10 longevity ingredients: typically sub-clinical doses of each; pay premium for marketing.
What the bear case looks like
Both NR and NMN may eventually fail to show hard-outcome benefit in the trials currently in progress. The plausible bear cases:
- CD38 dominance: aging-related NAD+ decline is driven by rising CD38 activity (an NAD+-consuming enzyme), not by declining synthesis. Adding more precursor doesn't fully address the underlying problem.
- Tissue heterogeneity: plasma NAD+ rise doesn't translate to brain, heart, or other relevant tissue NAD+ rises in humans.
- Mouse-to-human gap: rodent longevity benefits don't replicate in humans because rodent NAD+ biology differs in ways that matter.
- Cancer concerns: theoretical case that elevated NAD+ supports cellular proliferation and could increase cancer risk; not supported by current trial data but not refuted.
For users buying the NR or NMN bet, accept that the case is preliminary and the long-horizon outcome data could go either way.
See also
- NR compound page
- NMN compound page
- Senolytic supplements hub for the adjacent longevity-supplement class
- Biohacking supplements guide for tier-classification context
